For the entire history of hair transplant surgery, the procedure has been constrained by a strict mathematical limit: surgeons harvest healthy hair from the back of the head, leaving tiny fibrotic extraction holes and depleting a strictly finite donor supply. By delivering targeted micro-injections of verteporfin directly into fresh surgical extraction sites, this trial aims to mechanistically block the tension-driven scarring cascade, coaxing human skin to heal like an early-stage embryo—regenerating native skin architecture, dermal appendages, and brand-new hair follicles right inside the harvest wounds.
What Is It and How Does It Work?
The clinical mechanism centers on Yes-Associated Protein (YAP) Mechanotransduction Blockade and Engrailed-1 Fibroblast Inhibition—preventing the cellular mechanical signaling that forces wounded adult tissue to deposit fibrous scar collagen instead of regenerating complete skin organs.
-
The Fatal Scarring Reflex: When an FUE punch tool extracts a follicular unit, the sudden mechanical tension across the wound edges activates mechanosensitive ion channels and focal adhesion complexes. This signals the master transcriptional regulator YAP (Yes-associated protein) to migrate into the cell nucleus.
-
Activating Fibrotic Fibroblasts: Once in the nucleus, YAP switches on the pro-fibrotic Engrailed-1 (En1) lineage of fibroblasts. These cells ignore hair follicle assembly and rapidly dump thick, disorganized bundles of collagen, cementing a permanent fibrotic white scar where a living hair root once lived.
-
The Verteporfin Cellular Interception: Verteporfin—an FDA-approved benzoporphyrin photosensitizer originally designed for macular degeneration—binds directly to YAP without requiring laser light activation. It disrupts YAP’s interaction with TEAD transcription factors. Deprived of the mechanical tension command, En1-negative regenerative fibroblasts take over the wound. Rather than laying down a scar, they execute an embryonic-like repair program: activating native Wnt and Trps1 signaling, restoring subcutaneous fat, reforming sebaceous glands, and assembling new follicular bulbs de novo.
The Science: Clear Results and Human Clinical Evidence
Project V builds upon landmark wound-healing breakthroughs from Stanford University and independent physician case series:
-
Human Case Data Shows Up to 63% Hair Regrowth: In published human case evaluations of patients undergoing dermal incisional wounding with subcutaneous verteporfin injections, quantitative trichoscopy using the Ultimate Hair Densitometer demonstrated a mean increase of 63 percent in hair regrowth in traditional donor areas, with zero hypertrophic scarring.
-
Standardized Within-Patient Control in Project V: The newly launched Project V trial utilizes a split-scalp design where verteporfin-treated FUE donor extraction sites are compared directly against untreated control extraction sites within the same patient. This design eliminates variables like age, ethnicity, and systemic biology to objectively quantify changes in hair density, fibrotic depth, and follicular survival.
-
Complete Appendage Regeneration in Preclinical Models: Preclinical models demonstrated that wounds treated with a single, localized micro-injection of verteporfin healed with normal dermal architecture and full functional hair follicle coverage, whereas untreated control wounds formed completely bald, collagenous scars.
“If regenerative healing could eventually help preserve donor tissue, reduce fibrosis, or restore follicular structures following extraction, it could represent an important advancement for our field. Project V is designed to investigate that possibility scientifically. Our objective is not to make claims ahead of the evidence.”— Dr. Parsa Mohebi, Lead Investigator and Founder of Parsa Mohebi Hair Restoration.
When Will It Be Available?
-
Current Stage: Controlled human clinical trial (Project V) currently active and evaluating intrapatient FUE outcomes, running alongside ongoing European surgical scar-inhibition trials (such as SCARFREE-001).
-
Timeline: Initial dermatoscopic and density readouts from Project V are projected over the next 12 to 18 months, with standardized surgical protocols for commercial hair restoration clinics expected by 2027 to 2028.
How you can benefit from this treatment now
-
The End of the “Zero-Sum” Transplant: If verified, this breakthrough will transform hair transplantation from a rationing game into an infinite donor procedure. Instead of leaving scarred, thinned donor banks at the back of the head, surgeons will be able to harvest grafts repeatedly, allowing individuals with advanced Norwood 6 or 7 baldness to achieve full, dense coverage.
-
Guard Your Donor Zone Today: Because future regenerative transplants rely on harvesting healthy follicular cells to trigger the YAP-inhibition cascade, do not allow over-harvesting or aggressive punch sizes during any current surgical procedures.
-
Minimize Mechanical Scalp Tension: YAP activation is driven directly by mechanical skin tension. Avoid excessively tight hairstyles, aggressive mechanical traction, or harsh post-surgical stretching that increases tissue tension and accelerates fibrotic remodeling.
-
Avoid Compounded Verteporfin Injections Outside Controlled Protocols: Verteporfin is extremely light-sensitive and requires strict pharmaceutical reconstitution, precise sub-micromolar dosing, and protection from direct sunlight for up to 10 days post-procedure to avoid intense cutaneous phototoxicity. Avoid unverified cosmetic clinics offering off-label injections without controlled trial protocols.
Action: If you are considering an FUE hair transplant, ask your surgeon to map your remaining donor density using computerized trichoscopy to ensure your donor follicles are preserved for emerging regenerative surgical techniques.